Pulmonary Atresia Diagnostics and Treatment Market Highlights
A pulmonary atresia is a form of birth disease where the pulmonary valve which controls the flow of blood from the right ventricle to the pulmonary artery does not work effectively. In some cases, babies with pulmonary atresia may also have a small or missing, right ventricle that cannot properly pump blood to the lungs. In the case of pulmonary atresia, there is no threat to life, while the fetus is developing because the placenta is used to provide oxygen to the baby when the lungs are not functioning. Only after birth, the symptoms are noted and if the newborn baby turns blue or grey in color when the maternal source of oxygen is detached, it indicates that the newborn is suffering from the disease.
The Global Pulmonary Atresia Diagnostics and Treatment Market has been segmented on the basis of type, diagnosis, treatment and end users.
On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect. On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization. On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant. On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes and others.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/6487
Kyowa Pharma Chemical Co. Ltd,
Dickinson and Company,
C. R. Bard, Inc.,
B. Braun Melsungen AG,
JOHNSON & JOHNSON,
Cook Group Incorporated and Boston Scientific Corporation.
The Americas is projected to lead the pulmonary atresia diagnostics and treatment market in the forecast period. Increasing healthcare awareness, advancement in technology, medical tourism are some other factors that boost the growth of the market. According to the Centers for Disease Control and Prevention of US, the Congenital Heart Disease affects nearly 1% of births per year in the US and nearly 25% of babies are having critical Congenital Heart Disease.
The European market is expected to hold the second largest market share. The frequency of chromosomal irregularities was 3.6 per 1,000 births in Europe. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.
Asia-Pacific is projected to be the fastest growing region for the global pulmonary atresia diagnostics and treatment market in 2018. The diagnostic testing market, by volume, in India is controlled by microscopy testing. With increasing awareness and growing funding from care-based surveillance systems, private sectors and national governments the necessity for diagnostic testing procedures are projected to rise, thereby boosting the market development.
The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.
Ask to Expertise @ https://www.marketresearchfuture.com/enquiry/6487
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar